Opendata, web and dolomites

RESOLVE SIGNED

tPA-Nanoconstructs for Treating Acute Ischemic Stroke: a Technical and Commercial Analysis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESOLVE project word cloud

Explore the words cloud of the RESOLVE project. It provides you a very rough idea of what is the project "RESOLVE" about.

models    molecule    agents    biodegradation    diminish    efficacy    emotional    neurotoxicity    productivity    excretion    induces    fda    17m    revolutionize    tech    occlusion    re    portfolio    damage    treatments    discoidal    dpns    acute    fast    small    neurological    stroke       clot    societal    complications    5m    administration    thrombolysis    designed    validated    safer    longer    dissolution    death    thorough    rationally    people    clots    brain    economical    nanoconstructs    6m    validating    patients    pharmaceutical    protocols    considerable    drug    medical    direct    circulation    limitations    cerebral    20b    cohort    25b    approved    interaction    combination    secured    sale    commercial    statistics    toxic    polymeric    moved    markets    burden    alleviate    patent    whereas    lost    clinically    faster    profiles    companies    deaths    investing    administered    business    therapies    thrombectomy    blood    suffering    economic    estimate    market    ischemic    worldwide    vessels    survivors    healthcare    lasting    therapeutic    tpa    reports    thrombolytic    total    diagnostics    safely    causing    disabilities    50    fabrication    profile    indirect    stability    nano    strokes   

Project "RESOLVE" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 150˙000.00

Map

 Project objective

Acute ischemic strokes result from the occlusion of cerebral vessels by blood clots causing neurological complications, brain damage and death. Based on WHO reports, stroke affects 17M people per year worldwide, with 6M deaths and 5M survivors suffering long-lasting disabilities. Recent statistics estimate an EU direct healthcare cost for stroke of €20B and indirect costs, due to disabilities and lost productivity, of €25B. The two current treatments – thrombolysis and thrombectomy – come with limitations and considerable side effects. Thrombolysis can be safely administered only to a small cohort of patients (about 5%) whereas thrombectomy induces disabilities in 50% of the cases. Moved by the societal, economical, and emotional burden associated with stroke, this proposal aims at developing and validating more effective and less toxic therapies via the combination of the clinically approved molecule tPA and rationally-designed, discoidal polymeric nanoconstructs (DPNs). As compared to tPA, the proposed thrombolytic nano-agents (tPA-DPNs) are expected to provide faster blood clot dissolution; safer administration profile; longer blood circulation and stability. On the technical side, tPA-DPNs will be re-designed to improve their biodegradation and excretion profiles; validated in FDA-recognized stroke models for neurotoxicity and therapeutic efficacy. On the commercial side, a patent portfolio covering the fabrication and utilization of tPA-DPNs will be secured, together with thorough market and business analyses. This will facilitate the interaction with pharmaceutical companies that are investing in the fast growing markets of high-tech drug delivery systems and stroke diagnostics and therapies. tPA-DPNs are expected to alleviate the economic burden on healthcare systems, increase the total sale of thrombolytic agents, revolutionize the medical protocols for stroke management, and diminish the societal and emotional impact of stroke.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESOLVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESOLVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ERC VP CSA (2018)

Support to the Vice-Presidents of the ERC Scientific Council 2018

Read More  

CohoSing (2019)

Cohomology and Singularities

Read More  

AST (2019)

Automatic System Testing

Read More